The cost-effectiveness and monetary benefits of dabigatran in the prevention of arterial thromboembolism for patients with non-valvular atrial fibrillation in the Netherlands.
about
The cost-effectiveness and monetary benefits of dabigatran in the prevention of arterial thromboembolism for patients with non-valvular atrial fibrillation in the Netherlands.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh
2017年學術文章
@zh-hant
name
The cost-effectiveness and mon ...... brillation in the Netherlands.
@en
type
label
The cost-effectiveness and mon ...... brillation in the Netherlands.
@en
prefLabel
The cost-effectiveness and mon ...... brillation in the Netherlands.
@en
P2093
P2860
P1476
The cost-effectiveness and mon ...... ibrillation in the Netherlands
@en
P2093
Bregt Kappelhoff
Jelena Stevanovic
Maarten J Postma
Robert G Tieleman
P2860
P356
10.1080/13696998.2017.1372222
P407
P577
2017-09-07T00:00:00Z